Carbon-11-TASP 0410699

Drug Profile

Carbon-11-TASP 0410699

Alternative Names: [11C]TASP-0410699; Carbon-11-TASP-0410699; TASP0410699

Latest Information Update: 03 Feb 2016

Price : $50

At a glance

  • Originator Taisho Pharmaceutical
  • Class Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I CNS disorders

Most Recent Events

  • 13 May 2015 Taisho Pharmaceutical plans a phase I trial in Healthy volunteers in USA (NCT02448212)
  • 01 May 2015 Phase-I clinical trials in CNS disorders (Diagnosis) in USA (IV) (NCT02448212)
  • 01 Jan 2015 Taisho Pharmaceuticals completes a phase I trial in CNS disorders (Diagnosis) in USA (NCT02448212)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top